×
S&P 500   3,857.35 (-1.10%)
DOW   31,245.44 (-0.61%)
QQQ   288.34 (-1.41%)
AAPL   139.83 (-1.29%)
MSFT   260.65 (-1.60%)
META   166.94 (-1.50%)
GOOGL   2,274.71 (-1.81%)
AMZN   109.46 (-3.32%)
TSLA   716.80 (-2.44%)
NVDA   163.38 (-3.15%)
NIO   22.42 (-2.31%)
BABA   118.04 (-0.58%)
AMD   81.91 (-4.93%)
MU   58.91 (+0.22%)
CGC   3.67 (-3.17%)
T   20.85 (+0.34%)
GE   66.70 (-0.01%)
F   12.06 (+0.17%)
DIS   98.50 (+1.96%)
AMC   13.67 (-3.26%)
PFE   51.07 (-1.56%)
PYPL   73.91 (-2.67%)
NFLX   183.85 (-2.80%)
S&P 500   3,857.35 (-1.10%)
DOW   31,245.44 (-0.61%)
QQQ   288.34 (-1.41%)
AAPL   139.83 (-1.29%)
MSFT   260.65 (-1.60%)
META   166.94 (-1.50%)
GOOGL   2,274.71 (-1.81%)
AMZN   109.46 (-3.32%)
TSLA   716.80 (-2.44%)
NVDA   163.38 (-3.15%)
NIO   22.42 (-2.31%)
BABA   118.04 (-0.58%)
AMD   81.91 (-4.93%)
MU   58.91 (+0.22%)
CGC   3.67 (-3.17%)
T   20.85 (+0.34%)
GE   66.70 (-0.01%)
F   12.06 (+0.17%)
DIS   98.50 (+1.96%)
AMC   13.67 (-3.26%)
PFE   51.07 (-1.56%)
PYPL   73.91 (-2.67%)
NFLX   183.85 (-2.80%)
S&P 500   3,857.35 (-1.10%)
DOW   31,245.44 (-0.61%)
QQQ   288.34 (-1.41%)
AAPL   139.83 (-1.29%)
MSFT   260.65 (-1.60%)
META   166.94 (-1.50%)
GOOGL   2,274.71 (-1.81%)
AMZN   109.46 (-3.32%)
TSLA   716.80 (-2.44%)
NVDA   163.38 (-3.15%)
NIO   22.42 (-2.31%)
BABA   118.04 (-0.58%)
AMD   81.91 (-4.93%)
MU   58.91 (+0.22%)
CGC   3.67 (-3.17%)
T   20.85 (+0.34%)
GE   66.70 (-0.01%)
F   12.06 (+0.17%)
DIS   98.50 (+1.96%)
AMC   13.67 (-3.26%)
PFE   51.07 (-1.56%)
PYPL   73.91 (-2.67%)
NFLX   183.85 (-2.80%)
S&P 500   3,857.35 (-1.10%)
DOW   31,245.44 (-0.61%)
QQQ   288.34 (-1.41%)
AAPL   139.83 (-1.29%)
MSFT   260.65 (-1.60%)
META   166.94 (-1.50%)
GOOGL   2,274.71 (-1.81%)
AMZN   109.46 (-3.32%)
TSLA   716.80 (-2.44%)
NVDA   163.38 (-3.15%)
NIO   22.42 (-2.31%)
BABA   118.04 (-0.58%)
AMD   81.91 (-4.93%)
MU   58.91 (+0.22%)
CGC   3.67 (-3.17%)
T   20.85 (+0.34%)
GE   66.70 (-0.01%)
F   12.06 (+0.17%)
DIS   98.50 (+1.96%)
AMC   13.67 (-3.26%)
PFE   51.07 (-1.56%)
PYPL   73.91 (-2.67%)
NFLX   183.85 (-2.80%)
NASDAQ:AXSM

Axsome Therapeutics Stock Forecast, Price & News

$38.53
+1.50 (+4.05%)
(As of 06/28/2022 11:39 AM ET)
Add
Compare
Today's Range
$34.84
$39.70
50-Day Range
$21.74
$43.04
52-Week Range
$19.38
$74.10
Volume
70,167 shs
Average Volume
680,558 shs
Market Capitalization
$1.50 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$82.72
30 days | 90 days | 365 days | Advanced Chart

Receive AXSM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Axsome Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AXSM Stock Forecast (MarketRank)

Overall MarketRank

2.27 out of 5 stars

Medical Sector

295th out of 1,436 stocks

Pharmaceutical Preparations Industry

124th out of 687 stocks

Analyst Opinion: 3.4Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -
Axsome Therapeutics logo

About Axsome Therapeutics (NASDAQ:AXSM)

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

AXSM Stock News Headlines

Why Axsome Therapeutics Stock Is Soaring Today
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AXSM
Employees
108
Year Founded
N/A

Company Calendar

Last Earnings
5/02/2022
Today
6/28/2022
Next Earnings (Estimated)
8/08/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$82.72
High Stock Price Forecast
$180.00
Low Stock Price Forecast
$34.00
Forecasted Upside/Downside
+114.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.88888888888889
Research Coverage
9 Analysts

Profitability

Net Income
$-130.40 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.41 per share

Miscellaneous

Free Float
28,796,000
Market Cap
$1.50 billion
Optionable
Optionable
Beta
2.49














Axsome Therapeutics Frequently Asked Questions

Should I buy or sell Axsome Therapeutics stock right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Axsome Therapeutics in the last twelve months. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" Axsome Therapeutics stock.
View analyst ratings for Axsome Therapeutics
or view top-rated stocks.

What is Axsome Therapeutics' stock price forecast for 2022?

9 Wall Street analysts have issued 12-month price objectives for Axsome Therapeutics' stock. Their AXSM stock forecasts range from $34.00 to $180.00. On average, they predict Axsome Therapeutics' share price to reach $82.72 in the next year. This suggests a possible upside of 112.0% from the stock's current price.
View analysts' price targets for Axsome Therapeutics
or view top-rated stocks among Wall Street analysts.

How has Axsome Therapeutics' stock performed in 2022?

Axsome Therapeutics' stock was trading at $37.78 at the beginning of 2022. Since then, AXSM stock has increased by 3.3% and is now trading at $39.02.
View the best growth stocks for 2022 here
.

When is Axsome Therapeutics' next earnings date?

Axsome Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for Axsome Therapeutics
.

How were Axsome Therapeutics' earnings last quarter?

Axsome Therapeutics, Inc. (NASDAQ:AXSM) issued its quarterly earnings results on Monday, May, 2nd. The company reported ($1.03) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.02) by $0.01. During the same quarter last year, the business earned ($0.78) EPS.
View Axsome Therapeutics' earnings history
.

Who are Axsome Therapeutics' key executives?

Axsome Therapeutics' management team includes the following people:
  • Dr. Herriot Tabuteau M.D., Founder, Chairman, CEO & Pres (Age 54, Pay $1.06M)
  • Mr. Nick Pizzie CPA, M.B.A., Chief Financial Officer (Age 47, Pay $553.97k) (LinkedIn Profile)
  • Mr. Mark L. Jacobson, COO & Sec. (Age 39, Pay $554.72k)
  • Mr. Hunter Murdock Esq., Exec. VP of Legal & Compliance
  • Dr. Amanda Jones Pharm.D., Sr. VP of Clinical Devel. (Age 39)
  • Ms. Lori Englebert M.B.A., Exec. VP of Commercial & Bus. Devel. (Age 44)
  • Mr. Kevin Laliberte Pharm.D., Exec. VP of Product Strategy (Age 44)
  • Joseph Debrah-Afful CPA, M.B.A., Director of Fin.

What other stocks do shareholders of Axsome Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Axsome Therapeutics investors own include Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Dicerna Pharmaceuticals (DRNA), Amarin (AMRN), Sarepta Therapeutics (SRPT), Micron Technology (MU), Pfizer (PFE), AbbVie (ABBV), Alibaba Group (BABA) and Bristol-Myers Squibb (BMY).

When did Axsome Therapeutics IPO?

(AXSM) raised $52 million in an IPO on Thursday, November 19th 2015. The company issued 4,300,000 shares at a price of $11.00-$13.00 per share. Ladenburg Thalmann and Cantor Fitzgerald & Co. acted as the underwriters for the IPO and Brean Capital was co-manager.

What is Axsome Therapeutics' stock symbol?

Axsome Therapeutics trades on the NASDAQ under the ticker symbol "AXSM."

Who are Axsome Therapeutics' major shareholders?

Axsome Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (6.94%), BlackRock Inc. (5.38%), Alethea Capital Management LLC (2.68%), Fairmount Funds Management LLC (2.42%), Bellevue Group AG (1.85%) and State Street Corp (1.80%). Company insiders that own Axsome Therapeutics stock include Mark Coleman, Mark E Saad, Nick Pizzie and Roger Jeffs.
View institutional ownership trends for Axsome Therapeutics
.

Which major investors are selling Axsome Therapeutics stock?

AXSM stock was sold by a variety of institutional investors in the last quarter, including Iridian Asset Management LLC CT, Alethea Capital Management LLC, State Street Corp, BNP Paribas Arbitrage SA, Goldman Sachs Group Inc., Jane Street Group LLC, BlackRock Inc., and Bank of New York Mellon Corp.
View insider buying and selling activity for Axsome Therapeutics
or view top insider-selling stocks.

Which major investors are buying Axsome Therapeutics stock?

AXSM stock was purchased by a variety of institutional investors in the last quarter, including Fairmount Funds Management LLC, Ghost Tree Capital LLC, Worth Venture Partners LLC, Graham Capital Management L.P., Bellevue Group AG, Peregrine Capital Management LLC, Endurant Capital Management LP, and Simplex Trading LLC. Company insiders that have bought Axsome Therapeutics stock in the last two years include Mark Coleman, Mark E Saad, Nick Pizzie, and Roger Jeffs.
View insider buying and selling activity for Axsome Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Axsome Therapeutics?

Shares of AXSM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Axsome Therapeutics' stock price today?

One share of AXSM stock can currently be purchased for approximately $39.02.

How much money does Axsome Therapeutics make?

Axsome Therapeutics (NASDAQ:AXSM) has a market capitalization of $1.52 billion. The company earns $-130.40 million in net income (profit) each year or ($3.72) on an earnings per share basis.

How many employees does Axsome Therapeutics have?

Axsome Therapeutics employs 108 workers across the globe.

How can I contact Axsome Therapeutics?

Axsome Therapeutics' mailing address is 200 BROADWAY 3RD FLOOR, NEW YORK NY, 10038. The official website for Axsome Therapeutics is axsome.com. The company can be reached via phone at (212) 332-3241 or via fax at 212-320-0245.

This page (NASDAQ:AXSM) was last updated on 6/28/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.